Camargo

JULY 27, 2021

Gene therapy, which was in its infancy around 30 years ago, is now becoming a more prominent treatment method in many therapeutic areas, from personalized therapy to mass vaccinations against COVID-19. Gene therapy is a new therapeutic approach in which genes are used to treat or prevent diseases.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

The Pharma Data

JUNE 7, 2023

Bayer strengthens gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Bayer AG is joining forces with Acuitas Therapeutics, Inc., a biotechnology company specializing in the development of lipid nanoparticle (LNP) delivery systems for molecular therapeutics. Financial details were not disclosed.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

JUNE 15, 2023

Verve Therapeutics and Eli Lilly and Company have entered an exclusive research partnership to advance the former’s preclinical stage in vivo gene editing programme targeting lipoprotein(a) (Lp(a)) to treat atherosclerotic cardiovascular disease (ASCVD).

Gene Editing 130

Gene Editing Gene Gene Therapy In-Vivo 130

Drug Discovery World

MAY 6, 2024

Professor Dr Carla van Gils, Director of KWF, comments: “Many of academia’s most innovative agents can be difficult to bring into clinical development. Partnering with the Centre for Drug Development enables us to jump into the bench-to-bedside gap and fast track academic findings into clinical trials.

Drugs 57

Drugs Life Science Gene Editing Gene 57

pharmaphorum

SEPTEMBER 18, 2020

Vertex is already the top player in CF with a quartet of exon-skipping medicines that tackle the mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that underlies the disease, but there are still a sizeable group of patients with no treatment options.

Gene Editing 105

Gene Editing Gene Vaccination Vaccine 105

Drug Discovery World

SEPTEMBER 6, 2022

As we look to the future, many advanced therapy players are sticking to traditional cell and gene technologies like autologous cell therapies and gene therapy using adeno-associated viral vectors, but some are branching out to other models like allogeneic cell therapies, non-viral delivery methods and gene-editing technologies.

Gene Therapy 52

Gene Therapy Gene Gene Editing Manufacturing 52

The Pharma Data

DECEMBER 13, 2020

“Our company and R&D portfolio are entering into an exciting phase, as evidenced by the recent close of Series B financing and submission of the first gene editing product IND in China,” said Dong Wei, Ph.D.?CEO He received his B.S. degree from Henan Normal University, M.S. degree from Chinese Academy of Sciences and Ph.D.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

pharmaphorum

SEPTEMBER 29, 2020

In 2015, Adaptimmune and Universal Cells signed an agreement to drive the development of technologies leveraging gene-edited Induced Pluripotent Stem Cell (iPSC) lines, towards the development of allogeneic, or ‘off-the-shelf’, T-cell therapies.

Research 132

Research Gene Editing Gene Development 132

The Pharma Data

JANUARY 12, 2021

As a result, the company settled on four areas of focus – iPSC, allogenic CAR-T, genome mutations and gene editing. Each of the companies met strict criteria that includes assets in clinical development, an industry-leading platform and in-house manufacturing capabilities. The platform is already bearing fruit.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

Pharma Marketing Network

DECEMBER 21, 2020

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e.,

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

Drug Discovery World

FEBRUARY 28, 2024

CRISPR and brain cancer Meanwhile, elsewhere in the US, another exciting development – using CRISPR as a therapeutic approach – has possibilities for tackling brain cancer. Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers.

Development 62

Development Research Drugs Antibody 62

Drug Discovery World

JULY 3, 2023

In terms of the Bispecific and Multi-Specific Antibody Therapeutics programme, Dr Miguel Gaspar, Director, AstraZeneca, covered a breakout on T Cell redirection with bispecific antibodies, both in terms of strategies and clinical examples.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

Delveinsight

MARCH 2, 2021

To sum it, Chinook will manage clinical development and commercialization of product candidates while Evotec will be eligible for an undisclosed upfront payment, research funding, progress-dependent milestone payments, and tiered royalties on net sales for targets identified through the collaboration.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

Advarra

NOVEMBER 29, 2022

Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

The Pharma Data

NOVEMBER 3, 2020

According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

Delveinsight

SEPTEMBER 14, 2021

VOR33 was created through Vor’s genome eHSC platform combined with multiple therapeutic modalities to create treatment-resistant transplants that can improve the potential of targeted cancer therapies through cell therapy and gene editing. REX-001 is an MCT product in clinical development as patient-specific cellular immunotherapy.

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

The Pharma Data

JANUARY 17, 2021

To complement the internal capabilities, Aruvant is partnering with world-leading contract development manufacturing organizations. The strategic long-term manufacturing agreement with Lonza is a critical step to advancing the clinical development of ARU-1801 for sickle cell patients.

Manufacturing 52

Manufacturing Gene Therapy Trials Gene 52

Drug Discovery World

OCTOBER 16, 2023

Revvity is a global company, and we continue to develop our Cambridge-based expertise in cell and gene therapy to support the global pharmaceutical industry. Revvity has a specialised CRISPR gene editing and base editing Cambridge footprint and a long-standing relationship with the regional universities.

Drugs 73

Drugs Life Science Gene Therapy Genome 73

XTalks

FEBRUARY 10, 2023

Jeff Vassallo, Senior Director of Clinical Trial Management, at the global clinical contract research organization (CRO) Medpace. These details must be thoughtfully considered early in clinical development to ensure studies are completed within the projected timeline and budget,” added Dr. Vassallo.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Gene Therapy 52

The Pharma Data

DECEMBER 27, 2020

Notably, we never modify the DNA of these cells, which avoids some of the safety concerns that have been reported with certain gene-editing technologies. From these cells we apply proprietary methods to manufacture pure populations of only the cell types which we wish to use in patients. Forward-Looking Statements.

Manufacturing 52

Manufacturing Production Development Clinical Trials 52

The Pharma Data

DECEMBER 2, 2020

ERS Genomics – Ireland’s ERS Genomics Limited, and Germany’s Vivlion GmbH, announced a non-exclusive license agreement granting Vivlion access to ERS Genomics’ CRISPR/Cas9 patent portfolio, to enhance Vivlion’s gene editing reagents and screening services. for its cGMP-compliant CHOSOURCE platform. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

The Pharma Data

JANUARY 10, 2021

EDIT-301 is an experimental, ex vivo gene editing cell medicine in development for the treatment of sickle cell disease. Previously, the Company received Rare Pediatric Disease designation from the FDA for EDIT-301.

Medicine 52

Medicine Development Clinical Trials Clinical Trials 52

Drug Discovery World

MAY 30, 2023

FAPi PET is being developed as a highly sensitive imaging agent and can be used as a predictive biomarker for FAP targeted therapeutics, several of which are currently in clinical development. We expect this field to grow significantly in the coming years as these and other earlier stage assets are developed.

Research 52

Research Drugs Protein RNA 52

Drug Discovery World

NOVEMBER 30, 2023

Lonza’s integrated CMC strategy and timeline was presented, as well as case studies highlighting key approaches and technologies, including: vector design & integration, cell line selection, downstream process, analytical method and formulation development.

Antibody 57

Antibody Protein Engineer In-Vivo 57

Drug Discovery World

OCTOBER 7, 2022

To achieve this, we have brought our drug discovery sites together under a single leadership team, able to move at speed to partner with academia and industry partners to deliver novel therapies into clinical development. . RA: What’s the future outlook for Cancer Research Horizons? .

HR 52

HR Research Drugs Development 52

XTalks

AUGUST 2, 2023

With Blackstone Life Sciences, up to €300 million (around $315 million USD) will be invested to accelerate pivotal studies and clinical development programs for formulating the subcutaneous delivery of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. CRISPR Gene Editing Inventors Win Nobel Prize.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Pharmaceutical Technology

MAY 26, 2023

As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA. Rapid production will potentially enable researchers to overcome an industry bottleneck.

DNA 130

DNA Manufacturing Gene Therapy Gene 130